Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating the tumor microenvironment and tumor immunity.
This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?
Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.
No podcast episodes available.
TPTX earnings call for the period ending March 31, 2020.
TPTX earnings call for the period ending September 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.